The pharmacokinetics of cefaclor and cephalexin were characterized in patients with creatinine clearances ranging from 0 to 147 ml/min. Each of 24 fasted subjects received a single 500-mg oral dose of cefaclor, and 13 of these subjects later received 500 mg of cephalexin. Serum and urine levels of the antibiotics were measured by bioassay. The serum half-lives were highly correlated with corrected creatinine clearance (cefaclor r = 0.92, cephalexin r = 0.94). Linear regression estimates of the half-life of cefaclor were 2.3 h in the anephric patient and 40 min in the patient with a corrected creatinine clearance of 100 ml/min. For cephalexin, corresponding half-lives were 15.4 h and 58 min. We present a dosage nomogram for calculating the appropriate adjustments to the loading dose based on patient weight and maintenence dose based on corrected creatinine clearance.
3-cephem-4-carboxylic acid] is a new, orally effective cephalosporin antibiotic, similar in structure and spectrum of activity to cephalexin. It differs from cephalexin only in the substitution of a chlorine for the methyl group in the 3' position, but exhibits improved antibacterial activity against Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, and most enteric pathogens (9) ; Cefaclor appears to be well absorbed orally in humans; after a 250-mg oral dosage, cefaclor -achieves serum levels approximately one-half those of cephalexin (7) .
The objective of the present study was to characterize the pharmacokinetics. of orally administered cefaclor, particularly as altered by iunpaired renal function. Ir addition, we sought to develop a simple, useful dosage strategy for administering cefaclor and cephalexin to patients with various degrees of renal impairnent.
MATERIALS AND METHODS
Subjects. The subjects were adult male volunteers ranging in age from 22 to 76 years and in weight from 62 to 169 kg. Their creatinine clearances (Ccr) ranged from "normal" (greater than 100 ml/min) to less than 5 ml/min in those patients in our dialysis program (Tables 1 and 2) . A complete medical history excluded hematological or hepatic disease, or any history of sensitivity to penicillins. A hematocrit, leukocyte count, differential, urinalysis, and blood chemistry screen (including blood urea nitrogen, creatinine, bilirubin, alkaline phosphatase, glutamic oxalacetic transaminase, sodium, potassium, chloride, bicarbonate, calcium, and phosphorus) were performed before the study. The endogenous Ccr was determined from a 24-h urine collection before the study. Informed consent was obtained from all subjects.
Administration of drugs. Each of 24 fasting subjects received a single 500-mg oral dose of cefaclor. Thirteen of the subjects also received a single 500-mg dose of cephalexin at least 2 weeks later. Blood samples were taken immediately before and at 0.5, 1, 2, 3, 4, 6, and 8 h after dosing.
Antibiotic assays. Blood was collected in evacuated glass tubes without anticoagulant, and serum was obtained by centrifugation. Samples were stored in duplicate and frozen at -50°C until assayed. The cephalosporin concentration of the sera was determined by an agar well diffusion technique, using Bacillus subtilis as previously described (7) . The sensitivity of this assay is 0.3 Atg/ml, and complete standard curves were prepared for each assay by using human serum.
Pharmacokinetic analysis. Data for each subject were entered via a computer terminal, stored directly on disk files, and verified. Thereafter, data were manipulated only by pharmacokinetic and statistical computer programs.
The drugs were given orally, and 95% absorption was assumed for volume of distribution (Vd) analysis. The data were described in terms of a linear onecompartment model with first-order absorption lag. An iterative least-squares method was used to find the four parameters-Vd, absorption rate constant (K.), elimination rate constant (K.), and absorption lag (TTa)-which best described the observed serum levels for each subject (12) . As an initial step in the analysis, individual plots were generated by computer and examined by D.S. and K.B. (Fig. 3) by drawing two straight lines. The dose for each patient should be specified in terms of a desired peak serum drug level. Based on in vitro susceptibility studies, most strains of susceptible pathogens will be inhibited by concentrations of more than 4 ,g of cefaclor per ml (9) . A single dose of 250 mg in a 70-kg patient would be expected to give a peak serum level of 10 ,ug/ml, 500 mg would give 20 ,ug/ml, etc. The appropriate loading dose depends only on desired peak serum level and LBW. It is calculated by locating the LBW of the patient (bar 1) and the desired peak serum level (bar 2) and extending a straight line to the loading dose (bar 3).
The maintenance dose was chosen to replace the amount of drug lost during the dosage interval and thus depends on the loading dose and drug half-life. A line connecting the loading dose (bar 3) and CorCcr (bar 5) gives the best estimate of the correct maintenance dose (bar 4). 
DISCUSSION
The present study shows that oral cefaclor rapidly achieves therapeutic blood levels, as does cephalexin (Fig. 4) (10) . Peak blood levels after a 500-mg single oral dose ranged from 8.3 to 33.7 ,ug/ml, with a mean of 23.1 and standard deviation of 7.7 ,ug/ml, compared with a mean of 27.6 ,ug/ml for cephalexin. The absorption delay was slightly less for cefaclor, and peak -serum levels occurred at 53 min, versus 81 min for cephalexin.
The two drugs had similar kinetics in the patient with normal renal function (CorCcr of 100 ml/min), with half-lives of 40 and 58 min for cefaclor and cephalexin, respectively. For anephric patients, however, the difference was much greater (2.3 versus 15.4 h, respectively). This means that, at a CorCcr of 100 ml/min, 29% of cefaclor was probably being excreted by a nonrenal route, compared with only 6% for cephalexin. This is in close agreement with the 62% urinary recovery in this study and our previous study in which we found 70% urinary recovery for cefaclor and 96% recovery for cephalexin (7) . In any event, the half-life of cefaclor of 2 to 3 h for a CorCcr of 0 suggests that drug accumulation will be negligible even for a 6-h dosage regimen in anephric patients.
The metabolism of cefaclor has been examined in three species of laboratory animals (13) and in normal volunteers (7) . Cefaclor is chemically similar to other cephalosporins recently reviewed by Nightingale et al. (8) . Cephalexin exhibits biphasic blood levels (distribution phase) after rapid intravenous administration, which is better described by a two-compartment model such as that of Greene et al. (5) . Those authors conclude, however, that use of the simpler one-compartment model will not produce significant errors, since the dosage interval is long compared with drug half-life.
Intravenous cefaclor was not available for this study, so early (distribution phase) kinetics were not accessible. The absence of intravenous data also means that only the ratio of Vd and fraction absorbed were measurable. Animal studies of cefaclor and human studies of cephalexin show nearly complete (90 to 95%) oral absorption. In the interest of simplicity, we assumed 95% absorption and attributed all of the observed variation to Vd. This assumption does not affect estimates of other kinetic parameters.
Bloch et al. found similar kinetics for cefaclor in chronic renal failure (1) . Their results suggest a half-life of 62 min for Ccr of 100 and 2.9 h for Ccr of 0. Dosage nomograms. The cefaclor nomogram made very little adjustment for the maintenance dose, since the 6-h dosage interval was still more than three half-lives. The cephalexin nomogram, in contrast, recommended considerable adjustment in maintenance dose to give the same peak blood levels as Ccr decreased. Brogard et al. presented a table of recommended correction for cephalexin based on creatinine clearance and dosage interval (2). Our dosage nomograms provided a simple, rational method for choosing the loading dose based on patient weight and the maintenance dose based on CorCcr.
Cefaclor exhibits a bacteriological spectrum which compares favorably with that of cephalexin (9) . It appears to have the same low toxicity in acute and chronic studies. In this study, it was absorbed more rapidly and reached equivalent serum levels. In addition, the large nonrenal rate constant suggests that accumulation in the renally compromised host would be much less for cefaclor than for cephalexin. Furthermore, cephalexin has been implicated in nephrotoxicity, especially in combination with other drugs. The present findings suggest that cefaclor may be a safer antibiotic to use for selected bacterial infections in the presence of preexisting renal impairment when a cephalosporin is indicated.
